Evaluation of the Therapeutic Efficacy of the Newly Formulated Drug "Novostron" as an Experimental Basis for Clinical Trials.

Chronic wound infections driven by multidrug-resistant (MDR) bacteria continue to challenge modern medicine. This study introduces "Novostron", an innovative topical iodine-based formulation incorporating dextrin and metal halides designed to overcome the limitations of existing antiseptics, such as volatility and cytotoxicity. The complex's physicochemical properties were analyzed using infrared (IR) and ultraviolet (UV) spectroscopy, alongside thermogravimetric analysis, confirming its stability and robust iodine retention. Stability assessments revealed minimal iodine loss under optimal refrigerated conditions. In a rat skin wound model, the microbial load was significantly reduced to 1.4 ± 0.5 CFU/cm2 within 10 min postapplication, demonstrating rapid antimicrobial action. Wound-healing properties were evaluated on surgically induced wounds in mice, showing accelerated granulation tissue formation and epithelialization within 14 days, supported by histological findings. In infected wound models, combined therapy with "Novostron" and cefazolin enhanced immune responses (IgG and IgM levels), significantly reduced inflammation, and promoted robust tissue regeneration. Additionally, hematological studies revealed decreased leukocytes and thrombocytes, indicating reduced systemic inflammation. These findings suggest the potential of "Novostron" as a therapeutic agent for managing infected and surgical wounds, offering both antimicrobial and wound-healing benefits. However, clinical trials are essential to validate its safety, optimize its application protocol, and establish its efficacy for human use.